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Abstract   13 
Defensins represent an evolutionary ancient family of antimicrobial peptides that play diverse roles in 14 
human health and disease. Defensins are cationic cysteine-containing multifunctional peptides 15 
predominantly expressed by epithelial cells or neutrophils. Defensins play a key role in host innate 16 
immune responses to infection and, in addition to their classically described role as antimicrobial 17 
peptides, have also been implicated in immune modulation, fertility, development and wound healing. 18 
Aberrant expression of defensins is important in a number of inflammatory diseases as well as 19 
modulating host immune responses to bacteria, unicellular pathogens and viruses. In parallel with their 20 
role in immunity, in other species, defensins have evolved alternative functions, including the control 21 
of coat color in dogs. Defensin genes reside in complex genomic regions that are prone to structural 22 
variations and some defensin family members exhibit copy number variation (CNV). Structural 23 
variations have mediated, and continue to influence, the diversification and expression of defensin 24 
family members. This review highlights the work currently being done to better understand the 25 
genomic architecture of the β-defensin locus. It evaluates current evidence linking defensin copy 26 
number variation to autoimmune disease (i.e. Crohn’s disease and psoriasis) as well as the contribution 27 
CNV has in influencing immune responses to HIV infection.   28 
Word count: 2298    29 
1.  Introduction  30 
The defensins represent a class of cationic antimicrobial peptides that play pivotal roles in innate and 31 
adaptive immunity as well as roles in non-immunological processes. They constitute an ancient and 32 
diverse gene family, present in most multicellular organisms ranging, from plants, fungi, insects, 33 
molluscs and arachnids to mammals, including humans. During their evolutionary history, defensins 34 
have become highly diversified and have acquired novel functions in different species. Defensins have 35 
evolved to be highly efficient in their antimicrobial responses to a vast array of pathogens.   36 
The term “Defensins” was coined in 1985 after granule rich sediments were purified from human and 37 
rabbit neutrophils. This resulted in the characterization of the primary structure of the first six 38 
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neutrophils defensins (later known as α-defensins) (1–3). These early studies highlighted the structural 39 
hallmarks of defensins: That is, despite poor sequence identity across family members, all defensins 40 
possess a highly conserved motif of six cysteine residues that is key to their antimicrobial function. 41 
Subsequently, peptides with similar structure were discovered in the early 1990s in bovine (4) and 42 
mouse airway first (5) and subsequently in the human intestinal epithelium (6), and became known as 43 
β-defensins. The recent ability to interrogate genomic and proteomic data from a diverse array of 44 
species allowed the discovery and characterization of further members of the defensin gene family, 45 
intensifying interest in unveiling the roles of defensins in physiological and pathological processes.    46 
This review will primarily focus on the role of β-defensins in innate and adaptive immunity. We will 47 
highlight the methods currently employed to study the genomic architecture of this multifunctional 48 
gene family and how complex genetic variation has an impact on defensin host inflammatory 49 
responses.  50 
2.  Structure of β-defensins  51 
The β-defensin family members have poor sequence similarity, suggesting their antimicrobial activity 52 
is independent of their primary structure. Nuclear Magnetic Resonance (NMR) data has been used to 53 
evaluate the 3D structure of hBD1, hBD2 and hBD3 (7,8). These data confirm a high degree of 54 
similarity in their tertiary structures, despite their diverged amino acid sequences. The major element 55 
of the mature peptides secondary structure is represented by three β-strands arranged in an antiparallel 56 
sheet. The strands are held together by the three intramolecular disulfide bonds, formed between the 57 
six cysteines. The order of the disulfide bridges can vary, characterizing each family member. The 58 
amino-terminal region contains a short α-helical loop (which is absent in α-defensins). α-helical 59 
structures are common for protein regions that are incorporated into cell membranes and it has been 60 
proposed that this region of the β-defensin protein may anchor to bacteria cell walls (9). This is 61 
supported by the presence of two sites under positive selection located in the N- terminal region that 62 
may contribute to β-defensin functional diversity (10).  63 
Defensins do not appear to present a distinct hydrophobic core or a common pattern of charged or 64 
hydrophobic residues on the protein surface. This suggests peptide folding is driven and stabilized by 65 
disulfide bond formation alone. Moreover, the characteristic β-defensin 3D structure can be preserved 66 
and accommodates residues with different properties at most other positions. The first five amino acids 67 
of the mature peptide sequence is vital for correct protein folding under oxidative conditions. This 68 
favors the formation of the correct disulfide bonded pattern through the creation of a  69 
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key intermediate (11).  70 
3.  The evolution and divergent roles of β-defensins   71 
The evolutionary relationship between vertebrate and non-vertebrate defensins is still unclear, however 72 
phylogeny indicates that a primordial β-defensin is the common ancestor of all vertebrate defensins 73 
and this gene family expanded throughout vertebrate evolution (12). This hypothesis is supported by 74 
the discovery of β-defensin-like genes in phylogenetically distant vertebrates, including reptiles (13), 75 
birds (14) and teleost fishes (15). α-defensins are mammalian specific genes, and in humans α-defensin 76 
genes and different β-defensin genes are present on adjacent loci on chromosome 8p22-p23. The 77 
organization of this cluster is consistent with a model of multiple rounds of duplication and divergence 78 
under positive selection from a common ancestral gene that produced a cluster of diversified paralogous 79 
(16,17). This expansion occurred before the divergence of baboons and humans approximately 23-63 80 
million years ago (18,19). The present-day β-defensins probably evolved before mammals diverged 81 
from birds generating α-defensins in rodents, lagomorphs and primates after their divergence from 82 
other mammals (20). Recent evidence suggests convergent evolution of β-defensin copy number (CN) 83 
in primates, where independent origins have been sponsored by non-allelic homologous recombination 84 
between repeat units. For rhesus macaques this resulted in only a 20kb CNV region containing the 85 
human orthologue of human β-defensin 2 gene. In humans, recent work suggest a repeat unit of 322kb 86 
containing a number of β-defensin genes (21).  87 
Defensin family members possess a plethora of non-immune activities and it is instructive to provide 88 
some examples of the diverged nature of defensins function. Some members of the β-defensin family 89 
have an important role in mammalian reproduction (reviewed in (22). For example, there are five 90 
human defensin genes (DEFB125-DEFB129) clustered on chromosome 20, which are highly expressed 91 
in the epithelial cell layer of the epididymal duct, which secretes factors responsible for sperm 92 
maturation (23). Moreover, human DEFB118 was shown to be a potent antimicrobial peptide able to 93 
bind to sperm, probably providing protection from microorganisms present in the sperm ducts  94 
(24). It is noticeable how in long tailed macaque (Macaca fascicularis) and in rhesus macaque  95 
(Macaca mulatta) there is a similar β–defensin, called DEFB126, which is the principal protein that 96 
coats sperm (25); this coating is lost in the oviduct allowing fertilization to occur. In support of this, 97 
the deletion of a cluster of nine beta defensin genes in a mouse model, resulted in male sterility (26). 98 
In human studies, a common mutation in DEFB126 has been shown to impair sperm function and 99 
fertility (27).  100 
In a second example, recent studies have suggested that some β-defensin gene products including hBD1 101 
and hBD3, can interact with a family of melanocortin receptors, modulating pigment expression in 102 
dogs and possibly in humans (28). Typically, there are two genes that control the switching of pigment 103 
types: the melanocortin receptor 1 (Mc1r) and Agouti, encoding a ligand for the Mc1r which inhibits 104 
Mc1r signaling. Mc1r activation determines production of the dark pigment eumelanin exclusively, 105 
whereas Mc1r inhibition causes production of the lighter pigment pheomelanin. In dogs it was 106 
discovered that a mutation in the canine DEFB103 is responsible for the dominant inheritance of black 107 
coat color, which does not signal directly through Mc1r; this insight revealed a previously 108 
uncharacterized role of β–defensins in controlling skin pigmentation. Further studies have been 109 
conducted on human melanocytes, discovering a novel role of hBD3 as an antagonist of the α-110 
melanocyte-stimulating hormone (α-MSH, a known agonist of Mc1r, which stimulates cAMP signaling 111 
Machado et al.     Copy number variation of β-defensins  
  
 
        4  
to induce eumelanin production). As hBD3 is produced by keratinocytes, it can act as a paracrine factor 112 
on melanocytes modulating α-MSH effects on human pigmentation and consequently responses to UV 113 
(29). Moreover, it is known that melanocortin receptors are also involved in inflammatory and immune 114 
response modulation (30).  115 
4.  Expression of β-defensins  116 
  117 
Different β-defensins are present in different epithelial and mucosal tissues and can be constitutively 118 
expressed or induced in response to various stimuli (Table 2). Their anatomical distribution clearly 119 
reflects their ability to neutralize different pathogens and they are more abundant at sites prone to the 120 
microbial infections they are specific for. For example, hBD2 is strongly expressed in lung (31); hBD4 121 
is highly expressed in the stomach and testes (32), and hBD3 in the skin and tonsillar tissue (33). hBD1-122 
hBD4 are expressed in the respiratory tract, with constitutive expression of hBD1 (34) and inducible 123 
expression of hBD2-hBD4 in response to inflammation or infection (35). In keratinocytes there is 124 
constitutive mRNA expression of hBD1; conversely hBD2 expression is induced by 125 
lipopolysaccharides (LPS) or other bacterial epitopes in combination with interleukin-1β, released by 126 
resident monocyte-derived cells. hBD3 and hBD4 are inducible by stimulation with tumor necrosis 127 
factor (TNF), Toll-like receptor ligands, interferon (IFN)-γ or phorbolmyristate acetates [15]. hBD3 is 128 
also induced in response to local release of surface-bound EGFR (epidermal growth factor receptor) 129 
ligands via activation of metalloproteinases [46 47].  130 
  131 
5.  Antimicrobial activity of β-defensins   132 
  133 
The most studied function for β-defensins is their direct antimicrobial activity, through 134 
permeabilization of the pathogen membrane. Their exact mechanism of action is incompletely 135 
understood and two different models have been proposed. The first is a carpet model, where several 136 
antimicrobial peptides opsonize the pathogen surface bringing about necrosis, possibly disrupting the 137 
electrostatic charge across the membrane (36). The latter is a pore model, with several peptides 138 
oligomerizing and forming pore-like membrane defects that allow efflux of essential ions and nutrients 139 
(33).   140 
  141 
Defensins in vitro are active against gram negative and positive bacteria, unicellular parasites, viruses 142 
and yeast. Cationic peptides including β-defensins are attracted to the overall net negative charge 143 
generated by the outer envelope of Gram negative bacteria by phospholipids and phosphate groups on 144 
lipopolysaccharides and to the teichoic acid present on the surface of Gram positive bacteria.  145 
  146 
β-defensins also possess antiviral activity, interacting directly with the virus and indirectly with its 147 
target cells. Noticeably, in mammals β–defensins are also produced by the oral mucosa and they are 148 
active against HIV-1 virus: in particular hBD1 is constitutively expressed whereas the presence of a 149 
low HIV-1 viral load can stimulate the expression of hBD2 and hBD3 gene products through direct 150 
interaction with the virus. More specifically, hBD2 has been shown to down-regulate the HIV 151 
transcription of early reverse-transcribed DNA products (37) and hBD2 and hBD3 can mediate CXCR4 152 
down-regulation (but not CCR5) and internalization in immuno-stimulated peripheral blood 153 
mononuclear cells (38). This mechanism diminishes the chances of infection (39) and with other 154 
salivary gland components, could help to explain the oral mucosal natural resistance to HIV infection. 155 
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hBD3 also possesses an inhibitory effect on the influenza virus blocking the fusion of the viral 156 
membrane with the endosome of the host cell, through cross linking of the viral glycoproteins (40).  157 
Defensins have evolved to maximize their protective role, showing an extraordinary adaptation to 158 
different environmental challenges: for instance plant defensins are particularly active against fungal 159 
infections (Reviewed in (41), slowing down hyphal elongation, and some of them also evolved to gain 160 
an α-amylase inhibitory activity that can confer protection against herbivores (42,43).   161 
6.  Immune modulatory activity of β-defensins  162 
A role for defensins in proinflammatory responses and more recently immunosuppression (reviewed 163 
in (44) has been delineated over the last two decades. An initial important observation was that 164 
βdefensins can recruit immature dendritic cells and memory T cells to sites of infection and/or 165 
inflammation providing a link between the innate and adaptive arms of the immune system. A 166 
mechanism for this was provided by Oppenheim’s group where they demonstrated that natural and 167 
recombinant hBD2 could chemoattract human immature dendritic cells and memory T cells in vitro in 168 
a dose-dependent manner. This response was inhibited with the Gαi inhibitor pertussis toxin and 169 
suggested the possible involvement of a chemokine receptor(s) which was confirmed using antiCCR6 170 
blocking antibodies.   171 
TH17 cells express CCR6 and respond to β-defensins chemoattractant action. Furthermore, TH17 172 
cytokines (i.e. IL-17 and IL-22) induce expression of defensins from relevant cell types including 173 
primary keratinocytes potentially resulting in an amplification of TH17 responses (45). Increased TH17 174 
levels have been reported in different autoimmune diseases, such as multiple sclerosis (46), rheumatoid 175 
arthritis (47) and psoriasis (48), implicating β-defensin expression in autoimmunity. Given the role of 176 
defensins in chemoattracting monocytes and macrophages and the lack of CCR6 on these cell types 177 
other receptors were investigated that might mediate this chemoattractant activity. This resulted in the 178 
identification of CCR2 as a receptor for hBD2, hBD3 and their mouse orthologs (mBD4 and mBD14) 179 
(49)  180 
In addition to signaling through chemokine receptors, defensins have been shown to function through 181 
Toll like receptors (50,51).  hBD2 has been shown to be a natural ligand for the Toll-like-receptor-4 182 
(TLR-4), present on immature DCs, up-regulating co-stimulatory molecules and leading to DC 183 
maturation, and on CD4+ T cells, possibly stimulating their proliferation and survival (52). On bone 184 
marrow derived macrophages pre-treated with a recently identified mBD14 (53), TLR restimulation of 185 
these cells resulted in enhanced expression of pro-inflammatory mediators that was Gi protein 186 
dependent but independent of CCR2 or CCR6 signaling pathways (54).  187 
7.  β-defensin copy number variation and disease association studies  188 
In humans, β-defensins genes are organized into three main clusters at 8p23.1, 20p13 and 20q11.1, 189 
with another likely small cluster on chromosome 6p12 (55). At 8p23.1 a number of β-defensins are 190 
found on a repeat unit that is typically present at 2-8 copies in the population, with a modal copy 191 
number of 4. Each chromosome 8 copy can contain 1-8 copies of the repeat unit. The mutation rate at 192 
this locus is extremely fast (~0.7% per gamete) (56), indicative of the high level of plasticity in this 193 
genomic region. One-copy individuals are extremely rare (57,58), and suggest that the presence of a 194 
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null allele might be deleterious and selected against. At the other end of the DEFB copy number 195 
spectrum lies a proportion of high copies individuals (9-12 copies) with a cytogenetically visible CN 196 
amplification at 8p23.1 that has no phenotypic effect (59). These first experimental observations ignited 197 
further interest into the chromosome 8 DEFB cluster. Within the repeat unit there is DEFB4, DEFB103, 198 
DEFB104, DEFB105, DEFB106, DEFB107, SPAG11 and PRR23D1 (21,60) (Figure 1). The variation 199 
in the number of repeat units between individuals in the population and likely sequence variation 200 
between copies suggests that CNV of defensins may play a role in modulating defensin expression 201 
(61,62) and function. The consequences of copy number variation have been explored for a number of 202 
years and may include increased gene product, the production of fusion genes, the formation of extra 203 
coding domains or a position effect that alters expression of the gene product (63). This extensive 204 
structural genome variation in humans is particularly pertinent to diseases where defensins may be 205 
implicated in their pathology. This includes a number of autoimmune and infectious diseases (Table 206 
1).  207 
Mapping of the β-defensin CNV region has been challenging but recent data fixes the minimal length 208 
of the CNV at 157 kb (64) and a recent study using high density array comparative genomic 209 
hybridization combined with Paralogue Ratio Test (PRT) assays suggests it may be as large as 322kb 210 
(21). Because of the extensive copy number variation of defensins, robust methods are required to 211 
accurately interrogate copy number states in disease cohorts. Various locus specific techniques for CN 212 
determination have been utilized including  Multiplex Amplifiable Probe Hybridization (MAPH) (65), 213 
Multiple Ligation Probe Amplification (MLPA) (66) and PRT (67). The advantage of such techniques 214 
is the ability to obtain data that clusters around integer copy numbers providing a high degree of 215 
concordance between the methods and confidence in the copy number obtained. Association studies 216 
investigating some CNVs (i.e. CCL3L1/CCL4L2 in HIV) have provided conflicting results as the 217 
methods used did not generate data that clustered around integer copy number values (68,69). In some 218 
cases initial findings have been replicated in subsequent studies that have utilized more robust methods 219 
(70).    220 
In early association studies of multi-allelic CNV and disease, copy number variation of defensins was 221 
implicated in psoriasis. Individuals with more than five β-defensin copies presented a five-fold 222 
increased risk of developing psoriasis when compared to two copy individuals. In addition, there was 223 
a direct correlation between the number of copies and relative risk (odds ratio of 1.32) (71) This 224 
association was replicated (although with reduced odds ratio) in a subsequent study (72). In the case of 225 
an autoimmune condition, such as psoriasis, high copy number may contribute to the strong induction 226 
of hBD2 and hBD3, conferring protection from bacterial infections of the psoriatic lesions (73).   227 
Another disease strongly linked with defensin expression is Crohn’s disease (CD) where it has been 228 
demonstrated that reduced Paneth cell expression of defensins in the ileum results in ileal CD. 229 
Therefore defensin expression at this site may be important in maintaining the mucosal microbiota. 230 
NOD2 has been strongly implicated in the pathogenesis of CD from GWAS (74) giving a 17.1-fold 231 
increased risk for CD in homozygous or compound heterozygous individuals. NOD2 is a Nod like 232 
family receptor (NLR) member that controls expression of defensins in CD. Polymorphisms in NOD2 233 
result in reduced α-defensin expression and exacerbated disease. Polymorphism of the DEFB1 (non 234 
CNV gene) promoter has been associated with CD (75). So is there a role for copy number variation in 235 
CD? Previous studies indicated that α-defensin copy number may be important (76). However, recent 236 
work that accurately measured copy number using PRTs to determine copy number of DEFA1A3 237 
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determined that a SNP (rs4300027) is associated with DEFA1A3 CN in Europeans (77). This SNP was 238 
then used to indirectly interrogate GWAS data and suggested that α-defensins CNV may not be 239 
important in CD. A similar outcome was obtained with β-defensin copy number whereupon accurate 240 
measurement, there was no association with the CD (57) in contrast to previous reports (78,79). These 241 
results however do not exclude the role of α and β-defensin expression in the pathogenesis of CD but 242 
suggest that the individuals copy number state may not be important in this context.  243 
Given the suspected anti-viral role of defensins, it was suggested that defensin CNV may be important 244 
in host responses to HIV infection. There are a number of conflicting reports of the association between 245 
defensin copy number and HIV infection (80–82). A surprising finding from a cohort study that 246 
evaluated two sub-Saharan populations with HIV-1 or HIV-1/tuberculosis coinfection was that high 247 
copy number of β-defensins did not result in the predicted low viral load and did not improve immune 248 
reconstitution in patients (83). The converse was found suggesting that the immune modulatory 249 
properties of defensins may be subverted during HIV-1 infection. A model suggested to explain this 250 
apparently paradoxical result was that high copy number may promote increased recruitment of CCR6 251 
expressing cell types that are highly permissive for HIV-1 infection thus amplifying the foci of HIV-1 252 
infection.   253 
Conclusions  254 
Defensins play a key role in pathogen host interactions and are at the interface of innate and adaptive 255 
immunity. The complex genetic variation that underlies the evolutionary history of defensins and their 256 
biology is gradually being elucidated, suggesting defensin copy number variation is an important 257 
contributor to maximizing the host innate and adaptive response. The history of the defensin gene 258 
family is particularly paradigmatic given that many CNV loci in the human genome host immunity 259 
genes. Further studies should be conducted to better understand the genomic architecture of multi-260 
allelic CNVs. This will aid the development of robust assays that evaluate the overall impact that CNV 261 
has on and both physiological and pathological mechanisms of immunity.  262 
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DEFB cluster 
CN calls per 
diploid  
genome  
Sample size  Methods used for CN 
calling  
Association study?  Findings  Reference  
2-12  90 controls  
12 related individuals 
from 3 families with 
chr8p23 euchromatic 
variant (EV)  
MAPH  
SQ-FISH  
No  Average CN distribution of 2-7 for controls.   
Average CN distribution of 2-7 for EV carriers  
(Hollox et al.,  
2003)(84)  
2-8  27 unrelated samples  qPCR  No  Concordant CN for DEFB4 and DEFB103  (Linzmeier &  
Ganz, 2005)  
(85)  
2-10  355 patients with cystic 
fibrosis  
167 UK controls  
MAPH  Cystic fibrosis  DEFB CN is not associated with cystic fibrosis  (Hollox et al.,  
2005) (86)  
2-7 for DEFB4  44 samples  qPCR  No  Discordant CN for DEFB4, DEFB103 and DEFB104.   (Chen et al.,  
2006) (87)  
2-10  250 CD patients  
252 controls  
Array-CGH 
qPCR  
Crohn’s disease  <3 copies associated with CD (OR=3.06)  (Fellermann et 
al., 2006) (79)  
2-12  498 cases  
305 controls  
MAPH   
PRT  
Psoriasis  Higher CN associated with psoriasis RR=1.69 
>6 copies.  
(Hollox et al.,  
2007) (71)  
2-8  >800 samples  MAPH/REDVR, MLPA  
and array-CGH. All 
validated through PRT  
No  PRT is a reliable method for CNV analysis  (Armour et al.,  
2007) (67)  
2-9  42 samples  MLPA  No  Strict copy number concordance for all genes in 
the chr8p23.1 DEFB cluster  
(Groth et al.,  
2008) (88)  
1-12  208 offspring from 26  
CEPH families  
PRT   
Microsatellite analysis  
No  Fast germline copy number recombination of  
DEFB cluster (~0.7% per gamete)  
(Abu Bakar et 
al., 2009) (56)  
1-12 in CD 
patients 2-9 in 
controls  
466 CD patients  
329 controls  
  
qPCR  Crohn’s disease  >4 copies associated with CD (OR=1.54)  (Bentley et al.,  
2009) (78)  
1-10  1000 Crohn’s disease  
(CD) patients  
500 controls  
PRT on all samples qPCR 
on 625 samples  
Crohn’s disease  DEFB copy number  is not associated with CD 
(Higher accuracy in CN calling and a larger cohort 
compared with previous studies on CD)  
(Aldhous et al.,  
2010) (57)  
1-9  1,056 individuals from the 
HGDP-CEPH panel  
PRT  No  Recent selection of high-expressing DEFB103 gene 
copy in East Asia  
(Hardwick et al., 
2011) (89)  
1-9  1002 Ethiopian and  
Tanzanian HIV and  
HIV/TB patients  
PRT  HIV viral load in 
HIVonly and HIV/TB 
patients  
Increased HIV load prior to HAART (P = 0.005) 
and poor immune reconstitution following 
initiation of HAART (P = 0.003)  
(Hardwick et al., 
2012) (90)  
2-7  543 SLE patients  
112 AASV patients  
523 controls  
PRT  
515 samples validated 
with REDVR  
Systemic lupus 
erythematosus  ANCA 
associated small 
vasculitis (AASV)  
Higher CN associated with SLE and AASV.  
(SLE OR=1.2;  
AASV OR=1.5)  
(Zhou et al.,  
2012) (91)  
2-8  70 PDAC patients  
60 CP patients  
392 controls  
MLPA  Pancreatic ductal 
adenocarcinoma  
(PDAC)  
Chronic pancreatitis  
(CP)  
Protective effect of high DEFB CN against PDAC  
(Fisher’s exact test p=0.027)  
(Taudien et al.,  
2012) (92)  
1-9  2343 samples (689 
children and 1149 adults)  
PRT  Asthma   
Chronic obstructive 
pulmonary disease  
(COPD)  
DEFB CN is not associated with lung function in 
the general population (OR=0.89)  
(Wain et al.,  
2014) (93)  
2-9  113 otitis media 
prone children 259 
controls  
PRT  Susceptibility to otitis 
media  
DEFB CN associated with nasopharyngeal 
microbiota composition (with respect to the 
three predominant pathogens for otitis media:  
S.pneumoniae, M. catarrhalis and H. influenzae.   
(Jones et al.,  
2014) (94)  
Table 1. Summary of β-defensin CNV studies. AASV: ANCA Associated Small Vasculitis; array-CGH: array 
Comparative Genomic Hybridization; CD: Crohn’s disease; CEPH: Centre d'Etude du Polymorphisme Humain DNA 
panel; COPD: Chronic Obstructive Pulmonary Disease. CP: Chronic Pancreatitis; HAART: Highly Active Anti- 
Retroviral Therapy; HGDP: Human Genome Diversity cell line Panel; MAPH: Multiplex Amplifiable Probe  2 
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Hybridization; MLPA: Multiplex Ligation-Dependent Probe Amplification; PDAC: Pancreatic Ductal Adenocarcinoma;  3 
PRT: Paralogue Ratio Test; REDVR: Restriction Enzyme Digest Variant Ratio; SLE: Systemic Lupus Erythematosus;  4 
SQ-FISH: Semi-Quantitative Fluorescence in Situ Hybridization; TB: tuberculosis   5 
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Gene  Peptide  Tissue distribution  Synthesis and regulation  
Date  
DEFB4  Human β-defensin 2  
(HBD2)  
Oral (95) and nasal mucosa (96), lungs (31), plasma (97), 
salivary glands (95), small and large bowel (98), stomach 
(99), eyes (100), skin (101), and kidney with chronic 
infections (102).  
Inducible in response to viruses (103), bacteria (98), lipopolysaccharide  
(95,104), peptidoglycan (105), lipoproteins (106), cytokines (IL1α (98), 
IL-1β (107), TNF (108)), PMA (109), IFN-γ (HBD3 only,  and growth 
factors.   
TLR2-mediated expression of HBD2 (110).  
Constitutive expression on ocular surface (HBD3) (100). HBD3 CSE 
inducible (111).  
DEFB103  Human β-defensin 3  
(HBD3)  
Leukocytes, placenta, testis, heart, skeletal muscle (112), 
urinary tract (113)  
DEFB104  Human β-defensin 4  
(HBD4)  
Gastric antrum, oral mucosa (114) and testis  Constitutive or inducible in response to PMA (109), TNF-α (109) and 
bacteria.  
Constitutive mRNA expression in gingival keratinocytes (114).  
DEFB105  Human β-defensin 5  
(HBD5)  
Testis  In vitro antimicrobial activity against E.coli but not S.aureus (115).  
Constitutive mRNA expression in testis (116).  
HBD5 CSE inducible (111).  
DEFB106  Human β-defensin 6  
(HBD6)  
Testis , lung (117)  
DEFB107  Human β-defensin 7  
(HBD7)  
Oral mucosa (114), testis  Constitutive mRNA expression in gingival keratinocytes (114). 
Constitutive mRNA expression in testis (116).  
DEFB108  Human β-defensin 8  
(HBD8)  
Lung, oral mucosa (114)  Inducible by IL-1β (7) and Candida spp (114).  
Constitutive mRNA expression in testis (116).  
DEFB109  Human β-defensin 9  
(HBD9)  
Oral mucosa (114), lung, ocular surface (100)  Constitutive mRNA expression in gingival keratinocytes (114).  
Constitutive expression on ocular surface (100).  
mRNA almost ubiquitously expressed (117).  
CSE inducible (111).  
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